Article Text

Download PDFPDF
Time to rethink high-density lipoprotein?
  1. Sarah Wild1,
  2. Christopher D Byrne2
  1. 1
    Public Health Sciences, University of Edinburgh, Teviot Place, Edinburgh, UK
  2. 2
    Southampton General Hospital, Southampton, UK
  1. Professor C D Byrne, Department of Endocrinology and Metabolism, Mail Point 113, Level F, Centre Block, Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK; C.D.Byrne{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Decreasing low-density lipoprotein cholesterol (LDL-C) concentrations with statin treatment represents a key therapeutic strategy for primary and secondary prevention of cardiovascular disease, as summarised in the Joint British Societies 2 guidelines.1 However, the relative risk reduction for major vascular events for each mmol/l reduction in LDL-C associated with use of statins is only approximately 20%2 and many people treated with statins will go on to have their first or subsequent cardiovascular disease event. Consequently, there is a pressing need to develop alternative strategies to decrease risk of vascular disease.

A wealth of epidemiological observational data suggests there is a strong inverse causal relation between concentrations of high-density lipoprotein cholesterol (HDL-C) and risk of cardiovascular disease. For example, a review of four large prospective studies suggests that every increase of 0.03 mmol/l in HDL-C is associated with a 2–3% decreased risk of cardiovascular disease.3 This suggests that raising HDL-C could be a promising approach to reduce cardiovascular disease risk and a review in this issue of Heart by Hausenloy and Yellon considers this topic in detail (see page 706).4

However, there are some challenges to the conventional viewpoint that low HDL-C is a cardiovascular risk factor and that increasing HDL-C will be beneficial. For example, some genetic mutations that cause low HDL-C have not been associated with increased risk of cardiovascular disease.5 It is possible that the close association between HDL-C and other factors such as triglyceride levels, insulin sensitivity and a pro-inflammatory phenotype may contribute to the apparent relation between HDL-C and cardiovascular risk rather than HDL-C concentrations alone being the sole explanation. Plasma triglyceride concentrations have relatively large inter-individual and intra-individual variability and this makes it more difficult to establish associations with outcomes of interest than for more stable potential risk factors such …

View Full Text


  • Competing interests: CDB has received an Independent Research Grant from Pfizer.

Linked Articles